AbbVie's zumilokibart clears Phase II with long-interval dosing signal
AbbVie reports its injectable biologic zumilokibart cleared Phase II, with a profile the company says could support quarterly or twice-yearly maintenance dosing.
Topic
Zumilokibart
Topic
Zumilokibart
Zumilokibart Hits EASI-75 Endpoint in Phase 2 AD Trial
All three zumilokibart dose regimens beat placebo on EASI-75 at Week 16 in the Phase 2 APEX Part B study of moderate-to-severe at…
AbbVie Moves Zumilokibart Into Phase 3 Atopic Dermatitis Trials
AbbVie advances its IL-13-targeting biologic zumilokibart into Phase 3 atopic dermatitis trials, adding a pipeline candidate alon…
Zumilokibart Hits EASI-75 Primary Endpoint in Phase 2 Atopic Dermatitis Trial
AbbVie's zumilokibart met its EASI-75 primary endpoint in the 346-patient Phase 2 APEX Part B study, with the mid-dose regimen ad…
AbbVie Reports Positive Phase 2 APEX Part B Results for Zumilokibart
AbbVie presented positive Phase 2 APEX Part B results for the IL-13 inhibitor zumilokibart in moderate to severe atopic dermatiti…
Zumilokibart Hits Primary Endpoint in APEX Part B Atopic Dermatitis Trial
Zumilokibart met the primary endpoint in Part B of the APEX atopic dermatitis trial, HCPLive reports, setting up a potential Phas…
AbbVie's zumilokibart Hits Phase 2 Atopic Dermatitis Endpoint
AbbVie reports zumilokibart met its primary endpoint in a phase 2 atopic dermatitis trial, advancing a key pipeline asset toward…
Zumilokibart Clears Phase 2 in Atopic Dermatitis, Moves to Phase 3
Zumilokibart improved moderate-to-severe atopic dermatitis in a Phase 2 trial and will advance to Phase 3, with detailed efficacy…